Clinical Trials

1,000 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT07221474 2026-04-13

INTerpath-13

Phase 2 Recruiting

180 enrolled

Squamous Non-small Cell Lung Cancer

NCT07223047 2026-04-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

252 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

494 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07063745 2026-04-07

MountainTAP-29

Phase 2/3 Recruiting

590 enrolled

Lung Neoplasms

NCT05382299 2026-04-06

ASCENT-03

623 enrolled

Triple Negative Breast Neoplasms

NCT07491445 2026-04-06

RASolute 303

900 enrolled

Pancreatic Neoplasms

NCT02077881 2026-04-03

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

157 enrolled 18 charts

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

223 enrolled

Camurati-Engelmann Syndrome

NCT04251533 2026-04-03

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Triple Negative Breast Neoplasms

NCT06132958 2026-04-03

TroFuse-005

710 enrolled

Gynecologic

Endometrial Neoplasms

NCT07020221 2026-04-03

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

295 enrolled

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06312176 2026-04-02

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06422143 2026-04-02

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

851 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

1,130 enrolled

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06608927 2026-04-01

PRISM-1

610 enrolled

Pancreatic Neoplasms

NCT06926868 2026-04-01

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04104672 2026-03-31

ARC-8

196 enrolled

Pancreatic Neoplasms

NCT04205812 2026-03-31

POD1UM-304

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06103864 2026-03-31

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06360354 2026-03-31

MTAPESTRY 103

Phase 1 Recruiting

350 enrolled

Neoplasms, Pancreatic Neoplasms

NCT06692738 2026-03-31

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

880 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07076121 2026-03-31

A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Phase 2/3 Recruiting

470 enrolled

Pancreatic Neoplasms

NCT05586516 2026-03-30

A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer

Phase 1/2 Completed

16 enrolled

Fibrosis, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT06996782 2026-03-30

ALTAIR

152 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05017012 2026-03-27

MK-3475A-C18

72 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05982522 2026-03-27

IN10018 Combination Therapy in Previously-treated Solid Tumors

Phase 1/2 Withdrawn

Other solid neoplasm

Solid Tumor

NCT07259317 2026-03-27

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 2 Recruiting

60 enrolled

Adenocarcinoma, Carcinoma, Pancreatic Ductal

NCT07173751 2026-03-25

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

558 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

260 enrolled

CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT06917079 2026-03-23

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Recruiting

387 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT04894643 2026-03-20

PARC

Phase NA Recruiting

10 enrolled

Pancreatic Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05633667 2026-03-17

VELOCITY-Lung

Phase 2 Recruiting

270 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT05852691 2026-03-16

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

83 enrolled

Breast Neoplasms

NCT06767527 2026-03-16

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

416 enrolled

Triple Negative Breast Neoplasms

NCT06704724 2026-03-13

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

30 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT07024615 2026-03-13

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Phase 1 Recruiting

25 enrolled

Phase 2 Active not recruiting

Pancreatic Ductal Adenocarcinoma

NCT03816163 2026-03-12

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

393 enrolled

Pancreatic Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

770 enrolled 13 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT04083235 2026-03-09

NAPOLI 3

Phase 3 Completed

Phase 1/2 Active not recruiting

Metastatic Adenocarcinoma of the Pancreas

NCT06646055 2026-03-09

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

110 enrolled

Metastatic Pancreatic Ductal Adenocarcinoma

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06018337 2026-03-05

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

541 enrolled